June 5, 2008 - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY) announced that the positive preliminary data from its first clinical trial of Diabecell® for insulin dependent type 1 diabetes has encouraged the Company to expand the trial and proceed with testing higher doses.In LCT’s first Phase I/IIa trial of DiabeCell®, its lead product of encapsulated porcine insulin producing cells, 5 patients have been implanted with the lowest dose. As reported in the Company’s clinical update on 31 March 2008, there have been no significant adverse effects and a clinical effect was demonstrated with reduction in daily insulin requirement for up to six months follow up with satisfactory control of blood glucose... [PDF] Living Cell Technologies' Press Release -
